Second Trial Data Report: Clinical Substantiation for CVR Medical
VANCOUVER, BC / March 7, 2018 / CVR Medical Corp. (TSX.V: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) advisory staff member Dr. Phillip J. Bendick,
VANCOUVER, BC / March 7, 2018 / CVR Medical Corp. (TSX.V: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) advisory staff member Dr. Phillip J. Bendick,
CVR Medical Corp. is a med-tech organization dedicated to the development and advancement of revolutionary technology at work within the healthcare sector. Specifically, The Carotid Stenotic Scan (CSS), a groundbreaking tool which will be used to assess Carotid Arterial health in a way which is unavailable to the patient, healthcare provider, and the payor within the current system. By leveraging intellectual property, market and industry know-how, and key strategic relationships, CVR Medical has entered into a trajectory which will revolutionize healthcare and dramatically improve clinical outcomes.